Arimistane (ATD) Research Guide: Suicide Aromatase Inhibitor & Hormone Research
Research guide to Arimistane (androsta-3,5-diene-7,17-dione) — an irreversible suicide aromatase inhibitor, its mechanism vs anastrozole/exemestane, 25-75mg/day research dosing, estrogen rebound considerations after cessation, DHT effects, use in GH peptide stacks where IGF-1 increases aromatase activity, and WADA status.
TL;DR
- Arimistane is an irreversible (suicide) aromatase inhibitor — inactivates aromatase permanently vs competitive inhibitors
- Research dose: 25-75mg/day orally; must be tapered on cessation to avoid estrogen rebound
- Indicated in research contexts where testosterone-raising compounds (GH→IGF-1, prohormones) increase aromatase activity
- WADA banned; not appropriate for competitive athletes in tested sports
Disclaimer: For educational and research purposes only — not medical advice.
Arimistane (androsta-3,5-diene-7,17-dione, also abbreviated ATD) is a steroidal aromatase inhibitor that gained popularity as an over-the-counter alternative to pharmaceutical aromatase inhibitors. Its mechanism — irreversible binding to and inactivation of aromatase — classifies it as a "suicide inhibitor," giving it distinct pharmacological characteristics compared to reversible AIs.
Aromatase and Its Role in Hormone Balance
Aromatase (CYP19A1) is the enzyme responsible for converting androgens to estrogens:
- Testosterone → Estradiol (E2)
- Androstenedione → Estrone (E1)
- DHEA → Estrone (via androstenedione)
Aromatase is expressed in multiple tissues: fat, liver, breast, brain, bone, and gonads. In men, ~20% of estradiol is produced directly by the testes; ~80% comes from peripheral aromatization — making fat tissue (a major aromatase location) particularly important for estrogen management.
Mechanism: Irreversible vs Reversible AI
| Mechanism | Drug Example | How It Works | Recovery After Stopping |
|---|---|---|---|
| Competitive reversible | Anastrozole (Arimidex), Letrozole | Competes with androgens for aromatase active site; fully reversible | Immediate (half-life clearance) |
| Steroidal suicide | Exemestane (Aromasin), Arimistane | Binds irreversibly → enzyme permanently inactive | Slow (requires new enzyme synthesis) |
Clinical implications of irreversibility:
- Benefits: Sustained effect even with missed doses (enzyme recovers gradually)
- Risks: Overshoot — if too much aromatase is inhibited, estrogen drops too low, causing symptoms (fatigue, libido loss, joint pain, cognitive fog)
- Cessation risk: Estrogen rebound when stopping (new aromatase not yet inhibited)
Research Applications in Peptide Stacks
GH Peptides and IGF-1 Elevation
Growth hormone and IGF-1 increase aromatase expression in adipose tissue. This is relevant for researchers running sustained GH peptide protocols (Ipamorelin + MOD GRF), particularly those with higher body fat:
- Elevated GH → elevated IGF-1 → increased aromatase expression → higher estradiol from androgens
- For male researchers where estrogen balance is a research variable, adding a low-dose AI may be considered
Dose in this context: Arimistane 25mg/day or every other day — enough to offset the aromatase-stimulating effect of elevated IGF-1 without suppressing estrogen excessively.
Post-Cycle Context
Researchers who have completed courses of testosterone-affecting compounds (exogenous testosterone, SARM research) may use Arimistane as a pct support compound. However, compared to SERM-based PCT (clomiphene, tamoxifen), AI-only PCT does not restore endogenous testosterone production.
DHT-Like Properties
Arimistane has a steroidal structure derived from DHEA and possesses mild androgenic activity — some conversion to DHT-like metabolites has been proposed. This may contribute to the androgenic symptoms (acne, hair shedding in DHT-sensitive individuals) reported by some users at higher doses.
Dosing and Tapering Protocol
Standard research doses:
- Low: 25mg/day (mild AI effect; maintenance dose)
- Moderate: 50mg/day (meaningful estrogen reduction)
- High: 75mg/day (significant suppression; reserve for high-estrogen contexts)
Tapering protocol (to prevent estrogen rebound):
- Week 1-2: Current dose
- Week 3: Reduce by 50% (e.g., 50mg → 25mg)
- Week 4: 12.5mg or every other day
- Week 5: Stop completely
Comparison with Other AIs
| Compound | Type | Potency | Availability |
|---|---|---|---|
| Arimistane | Suicide steroidal | Moderate | OTC (supplement market, though regulatory scrutiny increasing) |
| Exemestane | Suicide steroidal | High | Prescription only (Aromasin) |
| Anastrozole | Reversible non-steroidal | High | Prescription only (Arimidex) |
| Letrozole | Reversible non-steroidal | Very high | Prescription only (Femara) |
| DIM | Mild (indirect) | Low | OTC supplement |
Frequently Asked Questions
Q: Can Arimistane suppress estrogen too much? A: Yes — low estrogen is problematic: joint pain, cognitive impairment, libido loss, cardiovascular risk (estrogen is cardioprotective in men), and bone density loss. Monitoring E2 (estradiol) via blood test is important. Target range for men: 20-30 pg/mL. If estrogen drops below 15 pg/mL, dose reduction or cessation is indicated.
Q: Is Arimistane legal for athletes? A: Arimistane is on the WADA prohibited list (in competition and out of competition) under "S4. Hormone and Metabolic Modulators." Competitive athletes subject to anti-doping testing should not use it. Non-competitive researchers are not bound by WADA rules.
Use the Stack Builder Calculator → /calculators/stack
For educational and research purposes only. Not medical advice.
Disclaimer: For educational and research purposes only. Nothing in this article constitutes medical advice, diagnosis, or treatment recommendation. All compounds discussed are research chemicals or investigational compounds unless explicitly noted otherwise. Consult a qualified healthcare professional before making any health-related decisions. Researchers must comply with all applicable laws and regulations in their jurisdiction.
Written by the Peptide Performance Calculator Research Team
Our team compiles research guides based on published literature for educational purposes. All content is for research use only — not medical advice. Read our disclaimer.
Frequently Asked Questions
What makes Arimistane a 'suicide' aromatase inhibitor?
Arimistane (androsta-3,5-diene-7,17-dione, ATD) binds irreversibly to aromatase (CYP19A1) — permanently inactivating the enzyme molecule it binds to. The aromatase enzyme cannot be regenerated; new enzyme must be synthesized. This is in contrast to reversible AIs (anastrozole, letrozole) which compete with substrate but can be displaced. Exemestane (Aromasin) is the pharmaceutical suicide AI; Arimistane is a cheaper OTC analog with similar mechanism.
What dose of Arimistane is used in research?
Research protocols typically use 25-75mg/day taken orally. Lower doses (25mg/day) for estrogen control during a research protocol with mild aromatization; higher doses (50-75mg) when significant estrogen suppression is needed. Cycling is important given the irreversible mechanism — abrupt discontinuation without tapering can cause estrogen rebound.
Why might estrogen rebound occur after stopping Arimistane?
Because Arimistane permanently inactivates aromatase molecules, enzyme levels are rebuilt from scratch during the treatment period. When Arimistane is stopped, the high circulating testosterone (not suppressed by AI) continues to aromatize — but now via newly synthesized aromatase that is not yet inhibited. This temporary window of high aromatization can produce elevated estrogen. Tapering the dose over 2-4 weeks before full cessation minimizes rebound.
New compound guides and calculator updates — no spam, unsubscribe any time.
Free Peptide Calculators
7 free calculators covering reconstitution, dosage, syringe units, half-life, injection volume, stack planning, and cycle duration — no account needed.